Norepinephrine for Hypotension in Cesarean Section
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cesarean Section
- Hypotension
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Only males
Description
Phenylephrine has a potent direct ? effect, with virtually no ? effects at clinical doses, however when given at higher than required doses, it may induce baroreceptor-mediated bradycardia with a consequent reduction in maternal cardiac output. Although ? agonist drugs are the most appropriate agent...
Phenylephrine has a potent direct ? effect, with virtually no ? effects at clinical doses, however when given at higher than required doses, it may induce baroreceptor-mediated bradycardia with a consequent reduction in maternal cardiac output. Although ? agonist drugs are the most appropriate agents to treat or prevent hypotension following spinal anaesthesia, those with a small amount of ? agonist activity may have the best profile (noradrenaline (norepinephrine) and metaraminol. Phenylephrine is currently recommended due to the amount of supporting data.Noradrenaline is the primary catecholamine released by postganglionic adrenergic nerves. It is a potent ? adrenergic agonist, with comparatively modest ? agonist activity.
Tracking Information
- NCT #
- NCT04367103
- Collaborators
- Not Provided
- Investigators
- Study Director: Mohamed M. Abdellatif, M.D. Assiut University Principal Investigator: Shimaa A. Husien, M.D. Assiut University
Get Well Soon